FDA and FTC warn Sensory Cloud that its FEND nasal mister is an unapproved, misbranded drug sold with COVID-19 prevention and treatment claims.
What happened
FDA reviewed hellofend.com on March 14, 2022, and FTC reviewed it on April 4, 2022; FDA also reviewed Facebook and Instagram pages that direct consumers to the site. FDA found FEND offered for sale in the U.S. with claims it can mitigate, prevent, treat, diagnose, or cure COVID-19. FDA says this makes it an unapproved new drug and a misbranded drug.
What FDA found
FEND is an unapproved new drug—a drug FDA has not approved—because it is sold with claims to prevent or treat COVID-19.
Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)FEND is misbranded—labeled with misleading claims—because its website and social media say it is safe or effective for COVID-19.
Section 502 of the FD&C Act, 21 U.S.C. § 352The company is prohibited from shipping FEND in interstate commerce while it is unapproved and misbranded.
Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The company advertised that FEND can prevent, treat, or slow COVID-19 without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. § 41 et seq.
What FDA wants
FDA asks the company to immediately stop selling any unapproved/unauthorized products for COVID-19 and, within 48 hours, email FDA describing the specific corrective steps, how it will prevent recurrence, and related documentation. FTC separately asks for certification within 48 hours that the unsubstantiated claims have ceased.
Who should pay attention
- companies selling nasal sprays or hygiene devices with COVID-19 claims
- retailers and online marketplaces listing unapproved COVID-19 products
- marketing and regulatory teams reviewing disease claims on websites and social media
This is a summary. Read the original letter on fda.gov.